Novome raises $33M series A, shoots for the gut with engineered microbes

Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the potential it offers for a non-invasive mechanism to deliver biologics to the gut, a long-standing industry goal. The funds will provide enough runway for the

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE